



Company Regn No: 200004639G

**FOR IMMEDIATE RELEASE**

**S\*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience  
Company of Singapore Award**

**Singapore, March 6, 2009** - S\*BIO Pte Ltd today announced that it has received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. Dr. Stephen Rhind, Senior Vice President Corporate Development, S\*BIO, received the award on behalf of the company, from Mr. S. Iswaran, Singapore's Senior Minister for Trade and Industry.

The Annual BioSpectrum awards recognize outstanding contributions to the growth of the biotechnology and life sciences industry in Asia. S\*BIO was chosen for its innovative business model and leading position in Singapore's biotechnology industry.

"We are proud to be named Singapore's emerging bioscience company of the year," said Dr. Jan-Anders Karlsson, CEO of S\*BIO. "Receiving this award not only reflects S\*BIO's leading role in oncology drug discovery and development but also demonstrates the commitment of Singapore's government to the local biomedical sciences industry.

"We thank everyone at S\*BIO whose combined efforts led to the significant progress we made in moving our leading candidates, the JAK2 inhibitors SB1518 and SB1578, the HDAC inhibitor SB939, and the multi-kinase inhibitor SB1317, through pre-clinical and clinical development."

**About BioSpectrum**

Launched in 2003 by Asia's leading specialty publishing company, CyberMedia India Ltd., BioSpectrum is India's and Asia-Pacific's most widely circulated and read Life Sciences media platform. It comes out in two monthly editions: India edition published from Bangalore and an Asian edition, printed and published from Singapore. The business-to-business magazine tracks the growth of life science companies, captures the emerging technological and entrepreneurial trends in the area of Life Sciences which include pharmaceutical, biotechnology, medical technology, bio-agriculture and bio-fuels. The combined readership of both the editions of the magazine, which is available in multiple formats as a fortnightly digital magazine, Web site, with updated daily news and daily electronic newsletter, is over 200,000. The readership includes the region's top policy makers, scientists, entrepreneurs, industry leaders, other influencers who are part of the Life Sciences ecosystem. The Web sites of the two editions have over 100,000 unique visitors.

**About S\*BIO Pte Ltd**



Company Regn No: 200004639G

S\*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S\*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S\*BIO's potent and orally-active JAK2 inhibitor, also entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S\*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S\*BIO's SB1317, a novel multi-kinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S\*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S\*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio\*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. More information about S\*BIO can be found at [www.sbio.com](http://www.sbio.com).

\*\*\*

**S\*BIO Pte Ltd:**

Stephen Keith Rhind, Ph.D.  
Senior Vice President, Corporate Development  
Tel: +65 6827 5000 (Singapore)  
Stephen\_rhind@sbio.com

**Russo Partners:**

Tony Russo +1 212-845-4251  
Tony.Russo@russopartnersllc.com  
Andreas Marathovouniotis +1 212-845-4235  
Andreas.Marathis@russopartnersllc.com